Early Phase Development: The Push for Faster Proof-of-Concept
In 2025, there is an intense focus on accelerating "Early Phase" development—the Phase I and II trials where a drug's safety and initial efficacy are first tested in humans. For biotech startups, reaching this "proof-of-concept" stage as quickly as possible is essential for securing the next round of funding or finding a larger partner. As a result, researchers are increasingly using...
0 Σχόλια 0 Μοιράστηκε 8 Views 0 Προεπισκόπηση